(200 days)
The FIRST RESPONSE® One-Step Digital Pregnancy Test is an in vitro diagnostic test device that incorporates a digital read out of the test result for the early detection of pregnancy (hCG in urine) by the lay user prior to the expected menses
The FIRST RESPONSE® One-Step Digital Pregnancy Test is a human chorionic gonadotropin (hCG) test system. It is a device intended for use by the lay user in the early detection of pregnancy by the detection of hCG, a placental hormone in urine. The FIRST RESPONSE® One-Step Digital Pregnancy Test labeling provides for the use of the test as early as three (3) days before the expected period. [Refer to K992232.] The device detects the presence of hCG in the urine of a pregnant woman by way of a series of immunochemical reactions via component reagents that are striped onto a chromatographic strip contained within a plastic housing, which is integral with the digital component that reads and displays. the result of the immunochemical reaction on the Display Screen of the device housing, as opposed to an analog display of the predicate device. The immunochemical reagents that are striped onto a chromatographic strip are unchanged from the predicate FIRST RESPONSE® One-Step Pregnancy Test.
Following the instructions for use provided with the device, the test is performed by placing the Absorbent Tip into the urine stream (alternatively a cup of urine may be used) for 5 seconds, then allowing the test to continue for 3 minutes. During this time, a blinking clock icon appears on the Display Screen of the device housing to indicate that the test is working. After the elapse of 3 minutes, a digital display of the result appears on the Display Screen: a "YES+" test result indicates that the pregnancy hormone (hCG) was detected (pregnant); a "-- NO" test result indicates that the pregnancy hormone (hCG) was not detected (not pregnant). A " ? " (question mark) appears when a test error has occurred.
This document describes the FIRST RESPONSE® One-Step Digital Pregnancy Test (K040866). While it provides details on the device, its intended use, and technological characteristics, it does not contain the specific acceptance criteria or the study data that proves the device meets those criteria.
Therefore, I cannot directly provide the requested table of acceptance criteria and reported device performance, nor can I answer questions about sample sizes, expert qualifications, adjudication methods, MRMC studies, or training set details from the provided text.
The document mainly focuses on the 510(k) summary, which outlines the device's substantial equivalence to predicate devices, and the FDA's clearance letter. This type of regulatory submission summarizes the device and its intended use but typically does not include the detailed study protocols, results, and acceptance criteria that would be found in a full clinical or performance study report.
To answer your request, I would need access to the actual performance study report, which is not included in the provided snippets.
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.